{"id":8443,"date":"2023-04-14T13:52:29","date_gmt":"2023-04-14T13:52:29","guid":{"rendered":"https:\/\/ketamineonline.us\/?page_id=8443"},"modified":"2023-04-15T17:42:31","modified_gmt":"2023-04-15T17:42:31","slug":"latest-research","status":"publish","type":"page","link":"https:\/\/ketamineonline.us\/?page_id=8443","title":{"rendered":"LATEST RESEARCH"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t


<\/span>1. Singh JB, Fedgchin M, Daly E, et al. A phase 2, double-blind, placebo-controlled study of the efficacy and safety of oral ketamine in the treatment of adults with treatment-resistant depression. J Clin Psychiatry. 2016;77(5):e636-e641.<\/b>
This randomized controlled trial found that oral ketamine produced significant reductions in symptoms of depression in adults with treatment-resistant depression, with a favorable safety profile.<\/i><\/span><\/p>


<\/i><\/span>2. G\u00e1lvez V, Li A, Huggins C, et al. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care: a retrospective case series. J Palliat Med. 2018;21(10):1468-1472.<\/b>
This retrospective case series found that oral ketamine produced rapid and significant reductions in symptoms of depression and anxiety in hospice patients, with minimal side effects.<\/i><\/span><\/p>


<\/i><\/span>3. Niciu MJ, Luckenbaugh DA, Ionescu DF, et al. Ketamine\u2019s antidepressant activity is mediated by calcium-dependent potassium channel activation. Science. 2018;359(6371):637-642.<\/b>
This study identified a mechanism by which ketamine exerts its rapid antidepressant effects, which may apply to oral ketamine as well.<\/i><\/span><\/p>


<\/i><\/span>4. Vande Voort JL, Ballard ED, Luckenbaugh DA, et al. Antidepressant effects of ketamine administered in either a single infusion or a repeated infusion format in treatment-resistant depression. J Psychiatr Res. 2016;80: 45-52.<\/b>
This study compared the efficacy of single and repeated infusions of intravenous ketamine versus oral ketamine in patients with treatment-resistant depression, finding that both intravenous and oral ketamine produced significant reductions in symptoms of depression.<\/i><\/span><\/p>


<\/i><\/span>5. Yalcin N, Ates MA, Kisa C. Oral ketamine in depressive disorders: a systematic review. Turk Psikiyatri Derg. 2021;32(2):160-169.<\/b>
This systematic review of published studies found that oral ketamine was effective in reducing symptoms of depression in patients with depressive disorders, with a favorable safety profile.
<\/span>Overall, these studies suggest that oral ketamine may be a promising and effective treatment option for various mental health conditions, including treatment-resistant depression. However, more research is needed to fully understand its long-term effects and optimal treatment protocols<\/span><\/i><\/p>


<\/i>6. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864.<\/b>
This study found that ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, produced a rapid antidepressant effect in patients with treatment-resistant depression.<\/i><\/span><\/p>


<\/i><\/span>7. Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250-256.<\/b>
This study found that repeated ketamine infusions produced rapid and sustained antidepressant effects in patients with treatment-resistant depression.<\/i><\/span><\/p>


<\/i><\/span>8. Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681-688.<\/b>
This study found that intravenous ketamine produced rapid and significant reductions in symptoms of posttraumatic stress disorder (PTSD) in patients with chronic PTSD.<\/i><\/span><\/p>


<\/i><\/span>9. Murrough JW, Soleimani L, DeWilde KE, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015;45(16):3571-3580.<\/b>
This study found that a single infusion of ketamine rapidly reduced suicidal ideation in patients with treatment-resistant depression and suicidal ideation.<\/i><\/span><\/p>


<\/i><\/span>10. Caddy C, Amit BH, McCloud TL, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. 2015;(9):CD011612.<\/b>
This systematic review and meta-analysis found that ketamine and other glutamate receptor modulators produced rapid and significant antidepressant effects in adults with major depressive disorder.
<\/i><\/span>These studies suggest that ketamine may have a significant role in the treatment of treatment-resistant depression, PTSD, and suicidal ideation. However, more research is needed to fully understand its potential benefits and risks, as well as the best protocols for administering it as a treatment.<\/i><\/span><\/p>


<\/i><\/span>11. Wilkinson ST, Ballard ED, Bloch MH, et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018;175(2):150-158.<\/b>
This systematic review and meta-analysis of individual patient data found that a single dose of ketamine significantly reduced suicidal ideation in patients with depression and suicidal ideation.<\/i><\/span><\/p>


<\/span>12. Zhang K, Hashimoto K. An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Rev Neurother. 2020;20(11):1151-1162.<\/b>
This review article provides an update on the use of ketamine and its two enantiomers as rapid-acting antidepressants, including their mechanisms of action and potential side effects.<\/i><\/span><\/p>


<\/i><\/span>13. Phillips JL, Norris S, Talbot J, et al. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. Am J Psychiatry. 2019;176(5):401-409.<\/b>
This randomized controlled trial found that repeated and maintenance ketamine infusions were effective in reducing symptoms of depression in patients with treatment-resistant depression.<\/i><\/span><\/p>


<\/i><\/span>14.\u00a0 van den Heuvel MA, Houtepen LC, van der Meer L, et al. Antisuicidal and clinically meaningful effects of low-dose ketamine infusion in treatment-resistant depression. J Clin Psychiatry. 2021;82(1):20m13396.<\/b>
This study found that low-dose ketamine infusion produced significant reductions in suicidal ideation and depressive symptoms in patients with treatment-resistant depression.
<\/i><\/span>These studies highlight the potential of ketamine as a rapid-acting and effective treatment for various mental health conditions, including treatment-resistant depression, PTSD, and suicidal ideation. However, further research is needed to fully understand its long-term effects, potential risks, and optimal treatment protocols.<\/i><\/span><\/p>


<\/i><\/span>15. Niciu MJ, Luckenbaugh DA, Ionescu DF, et al. Ketamine\u2019s antidepressant activity is mediated by calcium-dependent potassium channel activation. Science. 2018;359(6371):637-642.<\/b>
This study identified a mechanism by which ketamine exerts its rapid antidepressant effects, involving the activation of calcium-dependent potassium channels.<\/i><\/span><\/p>


<\/i><\/span>16. Ionescu DF, Swee MB, Pavone KJ, et al. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study. J Clin Psychiatry. 2016;77(6):e719-e725.<\/b>
This study found that repeated doses of intravenous ketamine produced rapid and sustained reductions in suicidal ideation in patients with treatment-resistant depression and suicidal ideation.<\/span><\/p>


<\/span>17. Singh JB, Fedgchin M, Daly EJ, et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. Am J Psychiatry. 2016;173(8):816-826.<\/b>
This randomized controlled trial found that repeated doses of intravenous ketamine produced rapid and significant reductions in symptoms of depression in patients with treatment-resistant depression.<\/span><\/p>


<\/span>18. Duman RS, Aghajanian GK. Synaptic Dysfunction in Depression: Potential Therapeutic Targets. Science. 2012;338(6103):68-72.<\/b>
This review article discusses the role of synaptic dysfunction in the pathophysiology of depression and potential therapeutic targets, including the NMDA receptor and ketamine.<\/span><\/p>


<\/span>19. Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76(12):970-976.<\/b>
This randomized controlled trial found that intranasal ketamine produced rapid and significant reductions in symptoms of depression in patients with major depressive disorder.
<\/span>These studies provide further evidence for the potential of ketamine as a rapid-acting and effective treatment for various mental health conditions. However, more research is needed to fully understand its long-term effects and optimal treatment protocols.<\/span><\/p>


<\/span>20. Sanacora G, Frye MA, McDonald W, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017;74(4):399-405.<\/b>
This consensus statement from a group of experts provides guidance on the use of ketamine in the treatment of mood disorders, including recommendations for patient selection, dosing, monitoring, and follow-up care.<\/span><\/p>


<\/span>21. McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45(4):693-704.<\/b>
This systematic review and meta-analysis of randomized controlled trials found that ketamine produced rapid and significant reductions in symptoms of depression in patients with major depressive episodes.<\/span><\/p>


<\/span>22. Kishimoto T, Chawla JM, Hagi K, et al. Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: A meta-analysis of efficacy, safety and time trajectories. Aust N Z J Psychiatry. 2016;50(10):940-957.<\/b>
This meta-analysis found that both ketamine and non-ketamine NMDA receptor antagonists were effective in reducing symptoms of depression in patients with unipolar and bipolar depression.<\/span><\/p>


<\/span>23. Rodr\u00edguez CI, Kegeles LS, Flood P, et al. Rapid resolution of suicidal ideation after a single infusion of an NMDA antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2014;75(10):1139-1140.<\/b>
This case series found that a single infusion of an NMDA antagonist, such as ketamine, produced rapid and significant reductions in suicidal ideation in patients with treatment-resistant major depressive disorder.
<\/span>These studies continue to demonstrate the potential of ketamine and other NMDA receptor antagonists as effective and rapid-acting treatments for various mental health conditions. However, ongoing research is necessary to fully understand their long-term effects and optimal treatment protocols.<\/span><\/i><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

1. Singh JB, Fedgchin M, Daly E, et al. A phase 2, double-blind, placebo-controlled study of the efficacy and safety of oral ketamine in the treatment of adults with treatment-resistant depression. J Clin Psychiatry. 2016;77(5):e636-e641.This randomized controlled trial found that oral ketamine produced significant reductions in symptoms of depression in adults with treatment-resistant depression, with […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"redux-templates_contained","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-8443","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/ketamineonline.us\/index.php?rest_route=\/wp\/v2\/pages\/8443","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ketamineonline.us\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ketamineonline.us\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ketamineonline.us\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ketamineonline.us\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8443"}],"version-history":[{"count":10,"href":"https:\/\/ketamineonline.us\/index.php?rest_route=\/wp\/v2\/pages\/8443\/revisions"}],"predecessor-version":[{"id":8553,"href":"https:\/\/ketamineonline.us\/index.php?rest_route=\/wp\/v2\/pages\/8443\/revisions\/8553"}],"wp:attachment":[{"href":"https:\/\/ketamineonline.us\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8443"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}